In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on United Therapeutics (UTHR), with a price target of $275.00.
The post Oppenheimer Believes United Therapeutics (UTHR) Still Has Room to Grow appeared first on Smarter Analyst.
In a report released today, Hartaj Singh...

https://www.smarteranalyst.com/new-blurbs/oppenheimer-believes-united-therapeutics-uthr-still-has-room-to-grow-2/

#SmarterAnalyst